Diabetic macular edema

This small Phase 2 study tested INV-102 eye drops in 19 people with diabetic macular edema, a swelling in the back of the eye caused by diabetes. Participants used the drops daily for 8 to 12 weeks. The goal was to see if the drops could improve retinal health and reduce swelling…

Researchers at Tanta University are testing whether a high-dose version of the eye injection aflibercept (8 mg) can improve vision in people with diabetic macular edema or retinal vein occlusion that has not responded well to earlier anti-VEGF treatments. The study enrolls 60 adu…

This phase 2 study tests a new treatment plan for diabetic macular edema, a condition that causes vision loss. Instead of waiting for severe swelling, patients receive two dexamethasone implants 12 weeks apart, then additional injections only as needed. The goal is to improve vis…

This trial tests whether a modified soft contact lens placed on the cornea during vitrectomy, a surgery for retinal disease, keeps the surgical view clearer than the standard method of intermittent saline irrigation. Researchers randomly assign 46 participants to receive either t…

This study tested an experimental drug called RZ402 in 94 people with diabetic macular edema, a condition that causes vision loss in people with diabetes. The goal was to see if the drug is safe and can reduce swelling in the retina and improve eyesight compared to a placebo. Par…

This phase 1 trial tests an experimental gene therapy called SKG0106, given as an injection into the eye, for people with diabetic macular edema, a complication of diabetes that causes blurred vision. The study enrolls a small group of adults with type 1 or type 2 diabetes whose …

This early-stage study tests a new drug called EYE201, given as three eye injections over 12 weeks, to see if it is safe and can help reduce swelling in the back of the eye. It includes people with three different eye conditions that cause vision loss: branch retinal vein occlusi…

This trial is testing MYL-1701P, a proposed biosimilar to the existing eye medication Eylea, in people with diabetic macular edema who have already completed an earlier study with the same drug. The goal is to see if continued treatment with MYL-1701P is safe and effective over a…

This trial investigates whether adding a dexamethasone implant (Ozurdex) to standard aflibercept (Eylea) injections can better control diabetic macular edema that has not responded to anti-VEGF therapy alone. Adults with persistent retinal swelling will receive either the combina…

This study tests the safety of an experimental eye injection called ONS-5010 (bevacizumab) in people with vision loss from wet age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion. Participants receive the injection and are monitored for side…

This trial tests an investigational drug called BAT5906, given as an eye injection, for people with diabetic macular edema—a condition where fluid builds up in the retina and blurs vision. The study compares two doses (2.5 mg and 4 mg) given multiple times to see which works best…

This study examines how well a biosimilar (a lower-cost copy) of the drug ranibizumab works for diabetic macular edema, a condition that causes vision loss in people with diabetes. Researchers will review medical records of 60 adults who received at least one injection of the bio…

This study tests an experimental drug called RO7446603, given alone or with existing medications (aflibercept or faricimab), for people with diabetic macular edema—a condition that causes vision loss due to diabetes. The trial has two parts: an early safety phase (Phase I) and a …

This study tests a drug called faricimab (VABYSMO) in people with diabetic macular edema, a condition where diabetes causes fluid buildup in the center of the retina, leading to vision loss. Participants receive injections of faricimab into the eye every four weeks. The goal is t…

This early study tested a new eye injection called ASKG712 in 10 people with diabetic macular edema, a condition where fluid builds up in the retina and blurs vision. The drug targets two proteins that cause leakage and abnormal blood vessel growth. The main goal was to check saf…

This study tested an oral medication called APX3330 in 103 adults with moderate to severe diabetic retinopathy, a leading cause of vision loss. The pill aims to reduce inflammation and low-oxygen stress in the eye. Researchers measured whether the drug could improve the severity …

This study tested a pre-filled syringe containing a high dose (8 mg) of the drug aflibercept for two eye conditions: diabetic macular edema and wet age-related macular degeneration. The main goal was to see if retina specialists could prepare and inject the drug easily and safely…

This study tested a new eye medication called PRO-169 against a standard drug (ranibizumab) for people with diabetic macular edema, a condition that causes vision loss in people with diabetes. About 509 adults with diabetes took part, receiving injections into the eye over one ye…

This phase 2 trial tested a new drug called vamikibart, given as an eye injection, for people with diabetic macular edema—a condition where diabetes causes fluid buildup in the center of the retina, leading to vision loss. The study involved 394 participants and compared vamikiba…

This study tested OCS-01, a steroid eye drop, in 552 people with diabetic macular edema (DME), a condition where fluid builds up in the eye and blurs vision. Participants used the drops several times daily for up to a year. The goal was to see if the drops improve vision and redu…

This study tested whether a steroid eye drop called OCS 01 can improve vision in people with diabetic macular edema, a common cause of vision loss in diabetes. Over 400 participants used the drops several times daily for a year. The goal was to see if this non-invasive treatment …

This study tested the safety and effectiveness of brolucizumab, a drug injected into the eye, for treating diabetic macular edema (DME) in 66 Indian patients. DME is a complication of diabetes that can cause vision loss. The study aimed to see how well the drug works in real-worl…

This study looked at whether faricimab injections can help people with diabetic retinopathy, a diabetes-related eye disease. Over 12 months, 60 patients received the treatment and doctors measured changes in the back of the eye. The goal was to see if the drug could reduce abnorm…

This study tested whether a higher dose (8 mg) of the drug aflibercept, given every 16 weeks, works as well as the standard dose (2 mg) given every 8 weeks for Chinese people with diabetic macular edema (DME), a diabetes-related eye condition that causes vision problems. 333 part…

This early-phase trial tested an investigational eye injection called OLN324 in 164 adults with either wet age-related macular degeneration (AMD) or diabetic macular edema (DME). The main goal was to check safety and how the drug moves in the body, with a preliminary look at whet…

This study looked at the long-term safety of faricimab, a medicine injected into the eye, for people with diabetic macular edema (DME). About 1,500 patients who had completed earlier studies received faricimab at personalized intervals. The main goal was to track side effects, no…

This study tested a new drug called EYE103, given as an injection into the eye, for people with diabetic macular edema (DME) or wet age-related macular degeneration (NVAMD). The trial had two parts: first, checking safety at increasing doses in about 12 people, then comparing two…

This completed Phase 4 study tested how much of the drug aflibercept gets into the bloodstream when a high dose (8 mg) is injected into both eyes of adults with diabetic macular edema or wet age-related macular degeneration. Fifty-one participants received the injections and had …

This phase 2a trial tested a new biologic drug called AG-73305, given as an injection into the eye, in 25 adults with diabetic macular edema (DME), a common cause of vision loss in people with diabetes. The study aimed to check the drug's safety and how well it works over 6 month…

This Phase II trial tested whether adding vamikibart to the standard treatment ranibizumab improves vision more than ranibizumab alone in people with diabetic macular edema. 187 participants received injections into the eye over 76 weeks. The study is complete, and results will s…

This study tested whether a steroid implant (Ozurdex) or anti-VEGF injections (Avastin, Lucentis, or Eylea) work better to prevent worsening of diabetic macular edema after cataract surgery. Sixteen adults with diabetes and pre-existing eye swelling received one treatment before …

This study tested the safety of aflibercept, an already-approved eye injection, in 100 Indian adults with diabetic macular edema (DME). Participants received injections every 4 weeks for 5 months, then every 8 weeks for a total of 48 weeks. The main goal was to track any side eff…

This phase 2 trial tested a new way to deliver dexamethasone directly to the back of the eye using tiny microspheres (OXU-001) compared to the standard Ozurdex implant. The study enrolled only 3 adults with diabetic macular edema to check safety and how well the treatment is tole…

Researchers are studying how measurements from two different optical coherence tomography (OCT) machines compare when scanning the back of the eye. The trial includes 338 adults with diabetes and diabetic macular oedema. Participants receive OCT scans on both a Heidelberg Spectra…

This study is testing a new eye imaging device called the VG200D, which uses advanced technology to take detailed pictures of the eye. Researchers want to see if it works as well as a standard device for measuring parts of the eye in people with glaucoma, retina problems, corneal…

This study tested a new imaging device called OCT angiography (OCTA) that takes 3D pictures of blood vessels in the back of the eye without needing dye injections. Researchers compared OCTA images to standard dye-based imaging in 88 people with retinal blood vessel problems or no…

This study tested whether playing slow tempo music before and during an eye injection (intravitreal injection) can reduce anxiety and pain. 144 adults took part, with half listening to music and the other half receiving standard care. Researchers measured anxiety using saliva tes…

This observational study follows about 236 adults with diabetic macular edema (DME) who did not respond well to anti-VEGF injections and are now starting treatment with a dexamethasone implant (DEX-I). The implant slowly releases steroid medication into the eye. Researchers will …

This study tests a microscope that has an OCT scanner built directly into it, allowing surgeons to take detailed cross-sectional images of the eye during surgery. The goal is to see if this setup is practical and whether the extra visual information helps guide surgical decisions…

This completed study observed 572 patients with neovascular age-related macular degeneration or diabetic macular edema who were already receiving brolucizumab injections. Researchers collected routine medical data to see how well the drug resolved fluid in the eye and improved vi…

This study reviews published research on artificial intelligence models that analyze retinal images to predict how well patients with diabetic macular edema will respond to treatments like anti-VEGF injections or laser therapy. By evaluating the accuracy of these AI tools, the re…

This trial tests a new device called P200TxE that takes detailed images of the back of the eye. Researchers want to see how well it captures images in people with retinal diseases like glaucoma or macular degeneration. The study involves adults aged 22 and older who have been dia…

This study tested whether artificial intelligence (AI) can help doctors detect retinal diseases from ultra-widefield eye images. 462 images were read by four eye doctors with different experience levels, both with and without AI assistance. The goal was to see if AI improves accu…

This study tested whether doctors could safely and correctly use a new prefilled syringe (SCD411) for eye injections. It included 33 adults with wet age-related macular degeneration, retinal vein occlusion, diabetic macular edema, or diabetic retinopathy. The main goal was to see…

This study looked at how much of a burden patients feel from repeated anti-VEGF eye injections for three different eye diseases: wet age-related macular degeneration, retinal vein occlusion, and diabetic macular edema. Researchers surveyed 393 patients about their treatment burde…

This study measured the thickness of the conjunctiva and Tenon's capsule (outer eye layers) in 736 people with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME), and in healthy volunteers of similar age. Researchers used a special eye scanner (SD…

This study looked at 360,000 French patients who received eye injections for conditions like age-related macular degeneration. The goal was to find out how often a serious eye infection called endophthalmitis happens within 28 days after the injection. Researchers analyzed data f…

This study looked at whether specific features on eye imaging scans can predict how well a person with diabetic macular edema will respond to treatment. Researchers analyzed images from 32 participants to find patterns linked to better or worse outcomes. The goal is to help docto…

This study looked at over 550,000 people who received Eylea® injections for eye conditions to find out how often retinal vasculitis (a rare eye inflammation) occurs. Researchers used a large US registry and medical records to confirm cases. The goal was to better understand the s…